Research Article

Parenteral Nutrition-Induced Cholestasis in Neonates: Where Does the Problem Lie?

Table 3

Patient characteristics within cholestasis group.

Omegaven ( )No Omegaven ( )

Gender, males (%)6 (100)9 (75)
Birth weight (g), Mean (SD)1, 598 ± 6142, 171 ± 1117
Preterm, (%)6 (100)7 (58.3)
IUGR, (%)6 (100)2 (16.7)
Apgar < 6, (%)6 (100)4 (36.4)
DOL conj bili above 50  mol/L, mean (SD)
1st conj bili above 50 μmol/L, mean (SD)
Duration of PN, median (IQR)52 (21, 69.8)38 (24.2–52.3)
DOL enteral feed started, median (IQR) (SD)37.0 (27.8–65.8)9.0 (2.5–17.5)
PN CH/kg/day, max, median (IQR)15.0 (13.1–16.5)14.0 (12.5–15.6)
PN lip/kg/day, max, median(IQR)3.0 (2.3–3.0)3.1 (3.0–3.5)
PN aa/kg/day, max, median (IQR)4.0 (3.6–4.0)3.5 (3.5–3.8)
Day start OV while on PN mean (SD) NA
Duration OV, median (IQR)21.0 (13.5–97.0)NA
Conj bili when OV started, ( mol/L), mean (SD) NA

PN: parenteral nutrition, IUGR: intrauterine growth restriction, conj bili: conjugated bilirubin, CH: carbohydrates, lip: lipids, aa: amino acids, OV: Omegaven, DOL: days of life.